Duloxetine 60 mg x2 compared to duloxetine 120 mg as a treatment for painful diabetic neuropathy in older persons

Reading time less than 1 minute
This page contains 1 evidence gap
  1. Duloxetine 60 mg x2 compared to duloxetine 120 mg as a treatment for painful diabetic neuropathy in older persons
Population:
Persons with painful diabetic neuropathy, 60 years or older
Intervention:
Duloxetin 60 mg x2
Comparison:
Duloxetine 120 mg x1
Outcomes:
Pain intensity, function and/or quality of life, adverse events, treatment compliance, care consumption

What evidence is needed?

More primary research is needed.

What evidence is available?

Reliable systematic reviews that show evidence gaps:

SBU. Läkemedelsbehandling av vanliga smärttillstånd hos äldre personer. Effekter, biverkningar samt upplevelser av vård [Pharmacological treatment of common pain conditions in older persons. A systematic review and assessment of medical, economic, social and ethical aspects]. Stockholm: Statens beredning för medicinsk och social utvärdering (SBU); 2020. SBU-rapport nr 315. ISBN 978-91-88437-57-0. More about the review

Reliable, but not updated, systematic reviews that show evidence gaps:

None identified

Registration number:
Published:
Research conducted after publication could potentially change the nature of the evidence.
To top

Evidence gap identifies methods or practices for which no conclusive systematic review of benefits and harms has been published. Gaps in scientific evidence appear on the SBU website to help researchers and granting agencies identify areas that are in need of research or systematic review. An additional objective is to offer healthcare and social service providers a basis for setting priorities.